Predicting Sensitivity of Non-Small-Cell Lung Cancer to Gefitinib: Is There a Role for P-Akt?
- 3 August 2004
- journal article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 96 (15) , 1117-1119
- https://doi.org/10.1093/jnci/djh244
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung CancerJAMA, 2003
- Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of CancerJournal of Clinical Oncology, 2003
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Epidermal growth factor receptor: mechanisms of activation and signallingExperimental Cell Research, 2003
- Studies leading to the identification of ZD1839 (iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancerBioorganic & Medicinal Chemistry Letters, 2001
- Untangling the ErbB signalling networkNature Reviews Molecular Cell Biology, 2001
- Epidermal growth factor receptor tyrosine kinaseBiochemical Pharmacology, 1994